Imeroprubart NCT07039916 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 3

Clinical phase

Recruiting

Recruitment status

231

Planned enrollment

2027-12-01

Primary-completion proxy

Executive view

NCT07039916 evaluates Imeroprubart in Myasthenia Gravis. The disclosed sponsor is Immunovant Sciences Ltd., the design is Interventional, and the geographic footprint is Argentina, Romania, Hungary, Czechia, United States, United Kingdom, Spain, Greece, Poland, Denmark, Mexico, Italy, Serbia, Germany. The first listed primary endpoint is Change from Baseline in MG-ADL Score for Antibody-positive Participants, assessed over Baseline to Week 12.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07039916 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Myasthenia Gravis landscape. Drug & Asset MCP drug_fetch was queried for Imeroprubart, while Company & Deal Intelligence MCP organization_fetch was queried for Immunovant Sciences Ltd..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07039916	Imeroprubart	Phase 3 / Recruiting	Immunovant Sciences Ltd.	Argentina, Romania, Hungary, Czechia, United States, United Kingdom, Spain, Greece, Poland, Denmark, Mexico, Italy, Serbia, Germany	Change from Baseline in MG-ADL Score for Antibody-positive Participants Baseline to Week 12	2027-12-01
NCT07058298	GC-012F	Early Phase 1 / Recruiting	Sponsor not reported	China	The frequency and severity of adverse events. Since signing the ICF until 24-week post-infusion or withdrawal from…	2027-02-13
NCT07022197	Anti-BAFFR CART(Tianjin Medical University General Hospital)	Phase 1/2 / Recruiting	Tianjin Medical University General Hospital	China	Types and incidence of dose-limiting toxicity (DLT) after BAFF-R CART cells infusion Up to 3 months post BAFF-R CART cells infusion	2027-12-30
NCT06987539	Inebilizumab-cdon	Phase 2 / Recruiting	Amgen, Inc.	Argentina, United States, Poland, Brazil, France, Spain	Maximum Observed Concentration (Cmax) of Inebilizumab Up to Week 52	2030-03-13
NCT06978738	Universal allogeneic anti-CD19/BCMA CAR T-cells(Changzhou No.2 People's Hospital)	Phase 1 / Not yet recruiting	Third Affiliated Hospital of Nanjing Medical University	China	The number and severity of dose-limiting toxicity (DLT) events Within 28 Days After UCAR T-cell Infusion	2027-05-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07039916 is a Phase 3, recruiting study with 231 planned participants. Allocation is Randomized, masking is Triple, and the intervention model is Parallel Assignment.

The primary endpoint is “Change from Baseline in MG-ADL Score for Antibody-positive Participants” over “Baseline to Week 12.” No additional primary-endpoint description was returned in the selected field set.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 231 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

The protocol identifies Imeroprubart as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Myasthenia Gravis. These records do not establish direct evidence for NCT07039916 unless the registration number matches.

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholi…

Phase 3; n=119; MG-ADL Total Score Change From Baseline(Least Squares Mean) = -1.90 points on a scale (90% Confidence Interval, -2.51 to -1.28); MG-ADL Total Score Change From Baseline(Least Squares Mean) = -3.35 points on a scale (90% Confidence Interval, -3.98 to -2.72) Source: https://clinicaltrials.gov/ct2/show/results/NCT06298552

Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial

Phase 3; n=238; exacerbation(26-week): HR = 0.41(95.0% CI, 0.24 - 0.7); exacerbation(26-week): HR = 0.41(95.0% CI, 0.24 - 0.7) Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42573995/

Assessment of sustained health- related quality of life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalized Myasthenia Gravis

Phase 3; n=129; EQ-5D-VAS(24-week) = 37.1 % ; EQ-5D-VAS(24-week) = 55.2 % Source: https://onlinelibrary-wiley-com.libproxy1.nus.edu.sg/journal/14681331

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Imeroprubart is indexed as Monoclonal antibody with FcRn biology and a global stage of Phase 3. The asset profile lists Immunovant, Inc. as an originator or developer.

Immunovant Sciences Ltd. is indexed in Bermuda. Develops restorative therapies for autoimmune diseases The record lists 2 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Imeroprubart is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07039916
Protocol source: https://clinicaltrials.gov/study/NCT07039916
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.

Imeroprubart in Myasthenia Gravis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Change from Baseline in MG-ADL Score for Antibody-positive Participants and 2027-12-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP